Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +15

Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

Antonius Baartscheer, Cees A. Schumacher, Rob C. I. Wüst et al. · Diabetologia · 2016 · 652 citations · Full text

Medicine, Cardiology, Pharmacology +16

Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors

Rolf Grempler, Leo Thomas, Matthias Eckhardt et al. · Diabetes Obesity and Metabolism · 2011 · 603 citations

Medicine, Pharmacokinetics, Pharmacology +17

Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy

Michael Arad, D. Woodrow Benson, Antonio R. Pérez‐Atayde et al. · Journal of Clinical Investigation · 2002 · 462 citations · Full text

Medicine, Cardiology, Genetics +13

Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy

Michael Arad, D. Woodrow Benson, Antonio R. Pérez‐Atayde et al. · Journal of Clinical Investigation · 2002 · 438 citations · Full text

Medicine, Cardiology, Genetics +13